The offering is expected to close Sept. The company said it intends to use the net proceeds from the offering for "general corporate purposes," which could include repayment of debt, working capital, payment of dividends and future acquisitions, among other things. If Gilead secures a deal, it would "re-energize the story and generate upside," Jefferies noted. The company could have assets that would set off any Hepatitis C declines, the firm said.
For the past 12 months Gilead Sciences, Inc. Many tried to catch it and lost a few fingers doing it. As a result, the stock now has upside technical opportunities and the terminal points of one can lead to the starting point of the other. But there are tough zones to crack along the way. When a stock falls for this long without a major change in its company fundamentals it creates value.
Gilead Sciences, Inc. It finally found footing in June of this year. And therein lies my opportunity. Source: Gilead Sciences.
It all starts in…. Leaders are, by definition, innovators. They do things other people have not done or dare not do. They do things in advance of other people.